Contribution of nosocomial transmission to *Klebsiella pneumoniae* neonatal sepsis in Africa and South Asia: a meta-analysis of infection clusters inferred from pathogen genomics and temporal data

Short title: Transmission of *Klebsiella pneumoniae* causing invasive disease in neonatal units

Erkison Ewomazino Odih[1], Jabir A Abdulahi[2], Anne V Amulele[3], Matthew Bates[4], Eva Heinz[5,6], Weiming Hu[7], Kajal Jain[8], Rindidzani Magobo[9,10], Courtney P Olwagen[11], John M Tembo[12], Tolbert Sonda[13], Jonathan Strysko[14,15], Caroline C Tigoi[3], Kyle Bittinger[7,16,17], Jennifer Cornick[18,19], Ebenezer Foster-Nyarko[1], Wilson Gumbi[3], Steven M Jones[7], Chileshe L Musyani[20,21], Carolyn M McGann[22,16], Ahmed M Moustafa[7,16,17], Patrick Musicha[19,23], James CL Mwansa[24], Moreka L Ndumba[3], Thomas D Stanton[25,26], Donwilliams O Omuoyo[3], Oliver Pearse[19,23], Laura T Phillips[1], Paul J Planet[16,17,27], Charlene MC Rodrigues[1,28,29], Fatou Secka[1], Kirsty Sands[30,31], Erin Theiller[17], Allan M Zuza[19,32], Sulagna Basu[33], Grace J Chan[34], Kenneth C Iregbu[35,36], Jean-Baptiste Mazarati[37,38], Semaria Solomon Alemayehu[39], Timothy R Walsh[30,40], Rabaab Zahra[41,42], Angela Dramowski[43], Sombo Fwoloshi[44], Appiah-Korang Labi[45], Lola Madrid[2,46], Noah Obeng-Nkrumah[47], David Ojok[48], Boaz D Wadugu[49], Andrew C Whitelaw[50,51], Anudita Bhargava[52], Atul Jindal[53], Ramesh K Agarwal[8], Alexander M Aiken[2], James A Berkley[54,55], Susan E Coffin[16,56], Nicholas A Feasey[19,27], Nelesh P Govender[9, 32], Davidson H Hamer[57,58], Shabir A Madhi[11,59], M Jeeva Sankar[8], Kelly L Wyres[1,25,26], Kathryn E Holt[1,25,*]

Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK
Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine, London, UK
Bioscience Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
School of Natural Sciences, University of Lincoln, Lincoln, UK
Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK
Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton, UK
Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, USA
Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa
Division of Public Health, Societies and Belonging, Human Sciences Research Council, Pretoria, South Africa
South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Infectious Diseases, HerpeZ, Lusaka, Zambia
Bioinformatics Unit, Kilimanjaro Clinical Research Institute, Moshi, Tanzania
Botswana-University of Pennsylvania Partnership, University of Pennsylvania, Gaborone, Botswana
Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
Center for Microbial Medicine, Children's Hospital of Philadelphia, Philadelphia, USA
Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK
Malawi Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi
Antimicrobial Resistance Unit, Zambia National Public Health Institute, Lusaka, Zambia
Levy Mwanawasa Medical University, Lusaka, Zambia
Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, USA
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
Directorate of Research and Post Graduate Studies, Lusaka Apex Medical University, Lusaka, Zambia

Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, Australia

Centre to Impact AMR, Monash University, Clayton, Victoria, Australia

The School of Medicine, University of St Andrews, St Andrews, UK

Department of Paediatrics, Imperial College Healthcare NHS Trust, London, UK

Pathogen Genomics Programme, UK Health Security Agency, London, UK

Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

Department of Medical Microbiology, Division of Infection and Immunity, Cardiff University, Cardiff, UK

Wits Mycology Division, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections, Kolkata, India

Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, USA

Medical Microbiology, University of Abuja, Abuja, Nigeria

National Hospital Abuja, Abuja, Nigeria

Health Sciences, INES-RUHENGERI, Musanze, Rwanda

INES Centre for Genomic Biology, Musanze, Rwanda

Department of Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia

International Centre for Antimicrobial Resistance Solutions, Copenhagen, Denmark

Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan

Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, St James's Hospital, Dublin 8, Ireland

Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa

University Teaching Hospital, University of Zambia, School of Medicine, Lusaka, Zambia

Department of Medical Microbiology, University of Ghana Medical School, Accra, Ghana

College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia

Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana

Central Laboratory, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

Biotechnology Laboratory, Kilimanjaro Clinical Research Institute, Moshi, Tanzania

Medical Microbiology and Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa

Microbiology, All India Institute of Medical Sciences, Raipur, India

Pediatrics, All India Institute of Medical Sciences, Raipur, India

Nuffield Department of Medicine, University of Oxford, Oxford, UK

Clinical Research Department, KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya

Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, USA

Department of Global Health, Boston University School of Public Health, Boston, MA, USA

Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

* Corresponding author
Email: kat.holt@lshtm.ac.uk

Abstract

Background

Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial resistant (AMR) infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of *K. pneumoniae* neonatal sepsis attributable to nosocomial transmission in African and South Asian countries.

Methods and Findings

We estimated the proportion of invasive *K. pneumoniae* disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences. Analysing 1,523 *K. pneumoniae* isolated from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs were associated with transmission clusters at multiple units and these were collectively responsible for two-thirds of all infections. Clustered isolates compared with singletons were more likely to carry carbapenemase genes (19.9% vs 10.2%, P = 0.003) or ESBL genes (94.2% vs 81.8%, P < 0.001).

Conclusions

Nosocomial transmission contributes to a substantial proportion of *K. pneumoniae* sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden.

Keywords: *Klebsiella pneumoniae*; neonatal sepsis; transmission; outbreak; Africa; South Asia; pathogen sequencing; genomics

Introduction

Sepsis is a leading cause of death among neonates, particularly in Africa and Asia, where the highest global incidence of neonatal mortality was recorded in 2022, with over 21 deaths per 1000 live births [1–3]. Bacterial infections are the most common cause of neonatal sepsis globally, with the predominant pathogens varying across geographical regions [4–10]. In Africa and Asia, *K. pneumoniae* is the primary cause of neonatal sepsis, and displays high rates of resistance to empirical antimicrobials recommended by WHO [5,11]. This makes the infections difficult to treat which contributes to higher neonatal mortality rates, mostly in low- and middle-income countries (LMICs) where the disease burden is highest and access to quality medical care and effective antibiotics is often limited [12,13].

Invasive bacterial disease in neonates is associated with two main transmission routes; vertical transmission from the mother, and nosocomial transmission from other sources including the hospital environment and healthcare workers [8,14,15]. As such, efforts to reduce the burden of neonatal sepsis focus on intrapartum antimicrobial prophylaxis [16], improving infection prevention and control (IPC) practices, early case identification, and sepsis management [17].

K. pneumoniae outbreaks in neonatal care units are well documented in the literature, including the use of pathogen whole-genome sequencing (WGS) to resolve transmission patterns and identify infection sources [18–23]. Nosocomial transmission in LMICs have been linked to poor IPC practices often resulting from limited resources, including inadequate access to water, hygiene, and sanitation resources, and sharing of beds and equipment [24–26]. In a retrospective WGS study of *K. pneumoniae* bloodstream infections over 20 years in a single hospital in Malawi, the majority (77%) of cases due to key lineages investigated (ST14, ST15, ST35, ST39) were attributable to nosocomial transmission, suggesting that more effective IPC practices supported by investment in IPC resources could help limit the incidence of neonatal sepsis [20].

To our knowledge, no study has quantified the contribution of nosocomial transmission to the burden of hospital-based *K. pneumoniae* neonatal sepsis across LMICs. This information is crucial to understand and contextualise the role of effective IPC measures in lowering the burden of neonatal sepsis in these settings, which is increasingly important as rising AMR further reduces treatment options. To address this gap, this study aimed to estimate the proportion of *K. pneumoniae* neonatal sepsis infections that are attributable to nosocomial transmission in neonatal care settings in LMICs in Africa and Asia.

Methods

Ethical considerations

Each contributing study obtained local ethical approval, details of ethics committees and approval numbers are listed in **Table S1**. The Baby GERMS-SA [27] and Malawi-Liverpool-Wellcome (MLW) Biobank [20] studies were granted consent waivers from local ethics committees for the use of routine diagnostic specimens/isolates and routine clinical data for research; all other studies obtained informed consent from the parents of participating neonates. Approval for the meta-analysis presented here was granted by the Observational / Interventions Research Ethics Committee of the London School of Hygiene and Tropical Medicine (ref #29931). Anonymised data from each primary study were shared for analysis, including date of specimen collection and hospital site identifier (where the study included more than one site), along with pathogen WGS data for the corresponding bacterial isolate.

Bacterial isolates and sequence analysis

Whole-genome sequences of *K. pneumoniae* isolated from neonates in LMICs in Asia and Africa were sourced from prospective clinical studies of neonatal sepsis: Burden of Antibiotic Resistance in Neonates from Developing Societies (BARNARDS) [5], Sepsis Prevention in Neonates in Zambia (SPINZ) [28–30], Baby GERMS-SA [27,31], Mortality from Bacterial Infections Resistant to Antibiotics (MBIRA) [32], Indian District Hospitals (DH) [33], Group B Strep Correlates of Protection Study (GBS-COP) [34], Neonatal Infections & MicroBIome (NIMBI-plus) [35], NeoBAC [36]; and long-term prospective surveillance of bloodstream infection at Queen Elizabeth Central Hospital in Blantyre, Malawi (MLW Biobank) [20] and Kilifi County Teaching and Referral Hospital (KCTRH) carried out by the Kenya Medical Research Institute (KEMRI)/Wellcome Trust Research Programme (KWTRP) [36]. Details of samples included from each study are given in **Table 1**, and characteristics of each study site are given in **Table 2** (this represents information provided by co-authors from each study team).

Table 1. Summary of isolates included in the study

Region	Country	Study [Ref]	Site no.	No. of genomes	Year of study	Temporal span (weeks)
Eastern Africa	*All*	-	-	**1124**	-	-
	Ethiopia	BARNARDS [5]	Site 1	94	2017	39
		MBIRA [32]	Site 2	31	2021	30
	Kenya	KWTRP [36]	Site 3	167	2013 - 2023	537
		NeoBAC [36]	Site 4	46	2021 - 2022	40
		NeoBAC [36]	Site 5	20	2021 - 2022	60
	Malawi	MBIRA [32]	Site 6A	27	2020 - 2021	55
		MLW [20]	Site 6B	362	2013 - 2020	377
	Rwanda	BARNARDS [5]	Site 7	15	2016 - 2017	79
	Tanzania	MBIRA [32]	Site 8	58	2021	39
	Zambia	MBIRA [32]	Site 9	19	2021	36
		SPINZ [28–30]	Site 10	285	2015 - 2017	72
Western Africa	*All*	-	-	**75**	-	-
	Ghana	MBIRA [32]	Site 11	25	2020 - 2021	45
	Nigeria	BARNARDS [5]	Site 12	34	2016 - 2017	96
		BARNARDS [5]	Site 13	16	2017	41
Southern Africa	*All*	-	-	**243**	-	-
	Botswana	NIMBI-plus [35]	Site 14	29	2022 - 2023	74
	South Africa	BARNARDS [5]	Site 15A	12	2016 - 2017	77
		Baby GERMS-SA [27,31]	Site 16	34	2019 - 2020	51
		Baby GERMS-SA [27,31]	Site 17	27	2019 - 2020	45
		Baby GERMS-SA [27,31]	Site 18	23	2019 - 2020	47
		Baby GERMS-SA [27,31]	Site 19	22	2019 - 2020	47
		Baby GERMS-SA [27,31]	Site 20	21	2019 - 2020	49
		Baby GERMS-SA [27,31]	Site 21	13	2019 - 2020	34
		GBS-COP [34]	Site 22	49	2019 - 2020	69
		MBIRA [32]	Site 15B	13	2021	25
South Asia	*All*	-	-	**81**	-	-
	Bangladesh	BARNARDS [5]	Site 23	17	2016 - 2017	89
	India	DH [33]	Site 24	34	2019 - 2022	116
	Pakistan	BARNARDS [5]	Site 25	30	2016 - 2017	81
Total	-	-	-	**1523**	-	-

Sites 6A and 6B represent the same neonatal unit that was included in two separate study protocols spanning different time periods as shown; data from these studies were treated separately in the meta-analysis, as sample collection and WGS protocols were conducted separately. Similarly, sites 15A and 15B represent the same neonatal unit that was included in two distinct studies.

Table 2. Characteristics of facilities included in the study

Region	Country	Location	Facility size	No. neonatal beds	Piped water available	Onsite neonatal surgical facilities	Site
Eastern Africa	Ethiopia	Urban	Very Large	30	Sometimes	Yes	Site 1
		Urban	Medium	40	Sometimes	Yes	Site 2
	Kenya	Rural	Large	75	Always	Yes	Site 3
		Urban	Large	100	Always	No	Site 4
		Urban	Large	90	Always	No	Site 5
	Malawi	Urban	Very Large	70	Mostly	Yes	Site 6A/6B
	Rwanda	Rural	Medium	15	Always	Yes	Site 7
	Tanzania	Urban	Very Large	100	Always	Yes	Site 8
	Zambia	Urban	Small	60	Mostly	Yes	Site 9
		Urban	Very Large	60	Sometimes	Yes	Site 10
Western Africa	Ghana	Urban	Small	55	Always	Yes	Site 11
	Nigeria	Urban	Very Large	30	Mostly	Yes	Site 12
		Urban	Large	20	Always	Yes	Site 13
Southern Africa	Botswana	Urban	Large	36	Mostly	Yes	Site 14
	South Africa	Urban	Very Large	132	Always	Yes	Site 15A/15B
		Urban	Very Large	71	Always	Yes	Site 16
		Urban	Large	36	Always	Yes	Site 17
		Urban	Large	72	Always	Yes	Site 18
		Urban	Large	45	Always	Yes	Site 19
		Urban	Large	60	Always	Yes	Site 20
		Urban	Large	92	Always	Yes	Site 21
		Urban	Very Large	200	Always	Yes	Site 22
South Asia	Bangladesh	Urban	Very Large	80	Mostly	Yes	Site 23
	India	Urban	Small	12	Always	No	Site 24
	Pakistan	Urban	Large	30	Always	Yes	Site 25

Facility size – Small: 50–150 beds, Medium: 151–300 beds, Large: 301–600 beds, Very Large: >600 beds.

For the prospective studies (BARNARDS, SPINZ, Baby GERMS-SA, MBIRA, DH, GBS-COP, NIMBI-plus, NeoBAC), blood culture was performed for all neonates with clinically suspected sepsis, and all blood culture isolates identified as *Klebsiella* that could be later revived for DNA extraction were included in sequencing and this meta-analysis. Baby GERMS-SA, GBS-COP, KWTRP, and MLW also included *Klebsiella* cultured from cerebrospinal fluid (CSF) of participants. For the long-term prospective surveillance studies (KWTRP, MLW), isolates from all positive blood or CSF cultures were stored for future research. At KWTRP, all neonates had blood culture on admission and again if their clinical condition deteriorated. At MLW, cultures were performed for all neonates with clinical signs of sepsis or meningitis, temperature >37.5 °C, or other signs of clinical deterioration.

For all studies, neonatal isolates identified as *Klebsiella*, which could later be revived for DNA extraction, were sequenced and those sequences that passed quality filters were included in this meta-analysis (see inclusion criteria below). Details of microbiology, sequencing, and bioinformatics methods used in each study, including the quality-control criteria applied prior to sharing genome sequences for this meta-analysis, have been reported previously [37] and are summarized in **Table S2**. Briefly, all studies utilized Illumina platforms and assembled genomes using either SKESA v2.3.0 (MBIRA) or SPAdes (all other studies). Genome assemblies were analysed using Kleborate v3.0 [38] to confirm species, identify multi-locus sequence types (STs), antimicrobial resistance (AMR) and hypervirulence determinants, and to identify capsular (K) loci (KL) and O types using Kaptive v3.0 [39].

Inclusion and exclusion criteria

Inclusion criteria for individual samples from the studies were: *K. pneumoniae* isolated from the blood or CSF of a neonate (defined as 0-28 days post birth), between 2013 and 2023 inclusive. CSF isolates were included from three studies (KWTRP surveillance, n=5; GBS-COP, n=2; MLW Biobank, n=31). Repeat *K. pneumoniae* isolates from the same participant with the same KL were excluded, ensuring that each genome represents a unique infection from an individual neonate (with the exception of MLW Biobank, for which archived isolates were not associated with patient identifiers thus precluding the exclusion of repeat isolates). Genome sequences identified as species other than *K. pneumoniae* or failing to meet the meta-analysis quality control criteria for assemblies (≤1,000 contigs and genome size 5–6.2 Mbp, as reported by Kleborate v3) were excluded. Additionally, study sites contributing fewer than 10 high-quality *K. pneumoniae* genomes that met the inclusion criteria were excluded (54 genomes from 12 sites). A flow diagram detailing sample inclusion is shown in **Figure S1**, including available information on the number of samples that were not stored, could not be revived for DNA extraction, failed sequencing, or did not meet genome quality control thresholds for each contributing study.

Identification of transmission clusters

Pairwise single nucleotide variant (SNV) distances were calculated using Pathogenwatch, which enumerates differences in a library of 1,972 core genes (totaling 2,172,367 bp) [40]. Transmission clusters were defined within each study site based on both the pairwise genetic distances (≤10 SNVs) and temporal distances (≤4 weeks based on date of specimen collection) between isolates. The igraph v1.4.1 R package [41] was used to identify single-linkage transmission clusters by constructing an undirected graph from an edge list of

isolate pairs. Each edge in the undirected graph represented a pairwise connection between isolates that were genetically similar (pairwise distance less than or equal to the specified genetic distance threshold), sampled within a specified temporal window (up to the specified temporal distance threshold), and isolated from the same site. Distinct transmission clusters were then defined as connected components of the resulting graph.

Estimation of cluster and transmission proportions

We estimated two key parameters – cluster proportion and transmission proportion – as indices of the contribution of transmission to the burden of *K. pneumoniae* neonatal disease in each neonatal care setting. The cluster proportion estimate was calculated as the number of *K. pneumoniae* isolates in clusters, divided by the total number of culture-confirmed and sequenced *K. pneumoniae*, for each site. The transmission proportion, on the other hand, was a conservative estimate of the proportion of *K. pneumoniae* isolates that were attributable to transmission. To estimate this, we excluded the first neonate in each cluster as a potential index patient, and assumed that all other infections within clusters were due to onward transmission in the unit. This almost certainly results in an underestimation of infections attributable to transmission, as the index patient may have also acquired *K. pneumoniae* from a contaminated source within the unit or an asymptomatically colonised neonate. The transmission proportion estimate was thus calculated as below:

$$\frac{total\ number\ of\ cluster\ isolates - number\ of\ clusters}{total\ number\ of\ isolates}.$$

Sensitivity analyses

We conducted a sensitivity analysis to determine the impact of the choice of genetic distance and temporal distance thresholds on the estimates of cluster proportion and transmission proportion. The estimates were calculated and compared across a range of genetic distance thresholds (range: 0–25 SNVs) and temporal distance thresholds (range: 1–52 weeks).

We also assessed how using different methods for calculating pairwise genetic distances between all isolate pairs could impact the obtained estimates. To do this, we generated reference-free SNV alignments of all genomes in the BARNARDS and SPINZ datasets using the split k-mer analysis (SKA) method with SKA2 v0.4.1 [42,43]. A SKA index was first built from the input assemblies using a k-mer size of 31, after which pairwise distances between all genomes were calculated using the "distance" subcommand with a minimum frequency threshold of 0.9 to include only core-genome SNVs. The cluster and transmission proportion estimates were re-calculated using these SKA-derived SNV distances and compared to those obtained using the Pathogenwatch core gene SNV distances.

Statistical analysis

All analyses and visualisations were performed using R v4.2.3 [44].

The methods for clustering infections, quantifying transmission, and exploring the sensitivity of the estimates to selected thresholds (as described above) are implemented in a species-agnostic Shiny web application

(https://klebsiella.shinyapps.io/transmission_estimator/), with source code available at https://github.com/klebgenomics/transmission_estimator (DOI: 10.5281/zenodo.17593948).

We performed meta-analysis of proportions using a generalised linear mixed model (GLMM) with a logit transformation to pool estimates of cluster proportion and transmission proportion across all study sites. A random effects model was applied to account for between-site variability, and 95% confidence intervals were computed using the Clopper-Pearson method. Heterogeneity between sites was assessed visually using Forest plots and quantitatively using the I^2 statistic. Subgroup analyses were undertaken to explore the variation of the estimates across geographical regions and countries. The meta-analysis was conducted using the metaprop function of the meta v7.0.0 R package [45]. To identify facility characteristics associated with transmission, we conducted a meta-regression analysis. The analysis was performed with the metareg function using the initial meta-analysis results as input and facility-level data (facility size, number of neonatal beds, availability of piped water, and onsite availability of neonatal surgical facilities) as covariates.

The proportions of isolates with extended-spectrum beta-lactamase (ESBL) and carbapenemase genes were compared between clustered and non-clustered cases using the Chi-squared test.

To model different bacterial features (ESBL gene carriage, carbapenemase gene carriage, ST) as potential predictors of transmission, we fitted a single logistic regression model in which each introduction was treated as a single observation, with the outcome recorded as transmission (cluster size ≥2) or no evidence of transmission (unclustered singleton case). For each cluster, each predictor was assigned the consensus value for that cluster (e.g. if 3 of 4 cases had ESBL gene/s detected, the cluster was recorded as ESBL-positive). Presence of ESBL (Kleborate score ≥1) or carbapenemase (Kleborate score ≥2) genes were encoded as binary variables. ST was encoded as a categorical variable, with one category per ST for which ≥3 unique introductions were observed, and the reference category being the group of all 123 'rare STs' with 1–2 unique introductions each (23.6% in the reference category). We also fitted two alternative models including O type or K locus (in addition to ESBL, carbapenemase, and ST) as potential predictors of transmission. O type was encoded as a categorical variable, with the most common type, O1 (51.6%), as the reference category. K locus was encoded as a categorical variable, with all K loci occurring in >1% of all introductions (n=25) compared against 'rare K loci' (those with ≤1% prevalence) as the reference category (n=55, 21.0% in the reference category). Models were fitted using Firth's bias reduction method, implemented in the logistf package in R (v1.26.0). Models with and without O serogroup or K locus were compared using the likelihood ratio test, using the anova function in base R.

Data availability

Sample-level data are described in **Table S3** (dates are shown as year only, to protect participant privacy). Raw whole-genome sequence data were deposited by the originating study teams in INSDC databases, under the following BioProjects: BARNARDS, PRJEB33565; SPINZ, PRJEB46513; MLW, PRJEB42462; NIMBI-plus, PRJNA1168993; DH, PRJEB70311; Baby GERMS-SA, PRJNA796486 and PRJNA1282934; GBS-COP, PRJNA1175467; KWTRP, PRJNA1265413; MBIRA: PRJNA1274034, NeoBAC, PRJNA1265413. All input data and code required to reproduce the results, figures, and

tables presented in this paper are available at

Results

Estimating transmission proportion

The study included 1,523 isolates from 27 sites in 13 countries, including Malawi (n=389), Zambia (n=304), Kenya (n=233), Ethiopia (n=125), Tanzania (n=58) and Rwanda (n=15) in Eastern Africa; Nigeria (n=50) and Ghana (n=25) in Western Africa; South Africa (n=214) and Botswana (n=29) in Southern Africa; India (n=34), Pakistan (n=30) and Bangladesh (n=17) in South Asia (**Table 1, Figure S2**). Sample size per site ranged from 12 to 362 genomes, with dates of isolation spanning 26 to 537 weeks per site. Six sites included data from only one year. A majority of the isolates were from Eastern Africa (n=1124), followed by Southern Africa (n=243), South Asia (n=81), and Western Africa (n=75). See **Table 2** for characteristics of neonatal care facilities included in the study.

Exploratory analyses of the sensitivity of clustering to choice of thresholds revealed that varying the SNV threshold within the range of 5 to 25 SNVs had minimal effect on the produced estimates (**Figure 1, Figure S3**). Within this distance threshold range (5–25 SNVs), we observed a mean difference of 3.8% (range 0–12%) in cluster proportion estimates and a mean difference of 3.5% (range 0–11%) in transmission proportion estimates, calculated as the mean of the differences between the estimates at 5 vs 25 SNVs thresholds at a fixed temporal threshold (4 weeks) and across all datasets. Below 5 SNVs, cluster proportion estimates varied more substantially (mean difference 21.9%, range 10–43%, between 0 and 5 SNVs), with the greatest change observed from 0 to 1 SNVs (mean difference 11.7%, range 0–24%), and stabilising approaching 5 (mean difference 1.6%, range 0–6%, between 4 and 5 SNVs). The cluster and transmission proportion estimates remained stable beyond 25 SNVs, even up to an extreme SNV threshold value of 1,000 (**Figure S4**). Compared to the genetic distance threshold, varying the temporal distance threshold between specimen collection dates had more of an impact on the transmission estimates. Nevertheless, there were minimal differences in the cluster proportion (mean difference = 7.3%, range 4–13%) and transmission proportion (mean difference = 7.3%, range 4–10%) estimated using 2 vs 8 weeks and a fixed genetic distance threshold of 10 SNVs. Further reducing the threshold to 1 week (i.e. only clustering isolates collected within 7 days) had a minimal impact in most sites (mean difference in cluster proportion of 4.4%, range 0–9%). To explore the sensitivity of our estimates to the choice of method for estimating genetic distance, we used a reference-free approach (SKA2) to estimate pairwise core-genome genetic distances for a subset of our *K. pneumoniae* data (isolates from BARNARDS [n=218], representing a multi-site study, and SPINZ [n=285], representing a large single-site study). This yielded very similar distance measures and near identical clustering results (see **Figure S5**). Given these findings, we adopted a genetic distance threshold of ≤10 SNVs and a temporal distance threshold of ≤4 weeks for clustering in the primary meta-analysis.

Figure 1. Sensitivity of the cluster proportion estimates to varying temporal and genetic distance thresholds.
The sub-panels show estimates for individual study datasets at different combinations of genetic distance threshold (x-axis) and temporal distance threshold ranges (as per figure legend).

A total of 156 transmission clusters were identified across all sites, comprising 1,035 unique infections (68.0%) (**Figure S6**). The identified clusters spanned between 1 and 249 days duration between the first and last cases (median: 14 days; interquartile range [IQR]: 6–28 days), with a median of 3 infections per cluster (range: 2–188, IQR: 2–5) (**Table S4)**. Almost half (73/156) of the clusters comprised only 2 infections. Excluding these 73 clusters as potential coincidental isolation of similar but independently introduced strains rather than nosocomial transmission, there were still 879 (57.7%) infections involved in 83 clusters affecting at least 3 patients each (median cluster size, 5 cases). Sixteen clusters overlapped either the beginning (n=7, cluster size: median = 3, range = 2–188) or the end (n=9, cluster size: median = 3, range = 2–32) of the sampling periods in the respective sites, suggesting that transmission may have been ongoing before sampling began or continued after sampling ended.

Meta-analysis of cluster and transmission proportion across all sites generated pooled estimates of 57.5% (95% confidence intervals [CI]: 46.0–68.2%) and 41.8% (95% CI: 31.1–53.5%), respectively (**Figure 2**). There was substantial heterogeneity between sites for both cluster proportion (range: 0–93%; I^2 = 88.7% [95% CI: 84.7–91.6%]) and transmission proportion (range: 0–87%; I^2 = 90.1% [86.9–92.6%]). In 10 of the 27 sites, at least half of all infections were attributable to transmission. Overall, at least a third of cases were attributable to transmission in 16 sites. Across all sites, the median number of clusters detected per site per year was three (IQR: 2–4, range: 0–13). Considering only clusters with ≥3 patients, we identified median one cluster per site per year (IQR: 1–3, range: 0–8). Subgroup analysis by region indicated that transmission proportions were highest in Eastern Africa (59% [41–75%]) and lowest in Western Africa (25% [17–36%]). Intermediate values

were estimated in Southern Africa (31% [19–47%]) and South Asia (38% [19–63%]) (**Figure S7**).

(A) Cluster proportion

(B) Transmission proportion

Figure 2. Pooled estimates of cluster and transmission proportion across sites.
(A) Cluster proportion **(B)** Transmission proportion. Plots show the point estimates (boxes) and 95% confidence intervals (horizontal bars) for each site. The pooled estimate and confidence interval, calculated using a generalised linear mixed model with logit transformation under a random effects model, are represented by the broken vertical line and point range horizontal line at the bottom of the plots.

To determine whether differences in study design and sampling methodology contributed to the heterogeneity observed between sites, we conducted two secondary meta-analyses

using data from two multi-site studies in our dataset (MBIRA and BARNARDS), each of which used a consistent study protocol across multiple sites [5,32]. The pooled estimate of transmission proportion across the seven BARNARDS sites was 26.1% (95% CI: 11.5–49.0%, range: 0-79%) and there was substantial heterogeneity between sites (I^2 = 88.6% [79.0%–93.8%]). The findings with the MBIRA dataset were similar, with a pooled transmission proportion estimate of 37.0% (95% CI: 15.8–64.8%, range: 8–86%) and significant heterogeneity (I^2 = 89.0% [78.8–94.3%] was observed across the six sites. Notably, the lowest cluster proportion observed in both these studies was at the same site, sampled under different protocols at different time periods (BARNARDS 15A, 2016-2017 and MBIRA 15B, 2021), but yielding similar results each time (0 clusters out of 12 isolates, and 1 clustered pair out of 13 isolates, respectively). This suggests that the observed heterogeneity in the full meta-analysis is unlikely to be influenced by primary study protocol differences alone, but may instead reflect variation in unmeasured factors such as demographic, geographic and/or site-specific variations. **Figure S8** shows a comparison of cluster proportion across different sites based on descriptive characteristics of the health facilities (summarised in **Table 2**). A secondary meta-regression analysis to identify facility characteristics associated with transmission showed a significant association for piped water availability, but not for facility size or number of neonatal beds. Notably facility size and bed count were also not associated with the number of *K. pneumoniae* isolates per site (R^2 <0.01, p=0.998 and R^2 = 0.14, p=0.053, respectively). For example, the lowest cluster proportions were observed at site 15, which is one of the largest neonatal units but as noted above had very few cases or clusters, potentially because it is one of the better-resourced facilities (located in Cape Town, South Africa with relatively strong microbiological diagnostics, surveillance and IPC capacity). Facilities with only occasional availability of piped water (two in Ethiopia, one in Zambia) had a significantly higher proportion of cases in clusters (87.7% [range: 64.5–89.4%]) than those where piped water was reported as being available most of the time (n=6; 42.5% [23.5–74.0%]; *P*=0.01) or always (n=18; 52.9% [0–93.5%]; *P*=0.026) (**Figure S8**). District hospitals with no surgical facilities onsite (two in Kenya, one in India) also had a significantly higher proportion of cases in clusters (88.2% [65.0–93.5%]) than hospitals with surgical facilities available onsite (n=24, 49.9% [0–89.4%], *P*=0.002) (**Figure S8**).

Genomic characteristics of transmitted *K. pneumoniae*

A total of 172 distinct *K. pneumoniae* STs were identified amongst the included isolates (**Table S5**). Of these, 57 STs were associated with at least one transmission cluster. We defined commonly transmitted STs as those that were identified in ≥3 transmission clusters in two or more sites. Fourteen STs met this definition (**Figure 3**), and these made up 63.8% (n=972/1523) of all infections, including 71.8% (n=743/1035) of clustered infections and 46.9% (n=229/488) of unclustered infections. Twelve of the 14 commonly transmitted STs were detected in ≥3 countries each, however ST152 and ST25 were each identified in just one country (South Africa and Malawi, respectively). The 14 commonly transmitted STs were responsible for most large clusters with ≥15 cases (n=6/10 clusters; 60%; **Figure 3D**), although four large clusters were caused by rare STs (ST6775, n=29; ST37, n=26; ST2004, n=20; and ST1414, n=17).

Figure 3. Commonly transmitted K. pneumoniae STs.
(A) Transmission profile showing number of clusters, number of sites where the STs were part of transmission clusters, and their odds ratios compared to rare STs in a logistic regression model to assess association with transmission. P-values for STs with a significant association with transmission are formatted in bold (see Table S8 for details of the logistic regression model). **(B)** Site distribution of cluster isolates. **(C)** Resistance distribution (proportion) of cluster isolates. Resistance scores are as reported by Kleborate based on the presence or absence of extended-spectrum beta-lactamase genes (ESBL), carbapenemase genes (Carb), and/or colistin resistance determinants (Col). **(D)** ST composition of large clusters. Points are coloured to indicate the 13 commonly transmitted STs and sized to indicate the number of isolates, as per the figure legend. Other STs are coloured in grey.

The majority of isolates (n=1384/1523, 90.9%) carried an ESBL or carbapenemase gene. Clusters were more likely to carry ESBL (94.2% of clusters (n=147/156) vs 81.8% of singletons (n=399/488), *P* = 0.00027) or carbapenemase genes (19.9% of clusters (n=31/156) vs 10.2% of singletons (n=50/488), *P* = 0.0025) (**Table S6**). ESBL gene carriage was also significantly higher among instances (singleton infections or deduplicated clusters) of the 14 commonly transmitted STs compared to those of the other 158 STs (94.2% (n=308/327) vs 75.1% (n=238/317), *P* < 0.0001), but carbapenemase gene carriage rates did not differ significantly between the two groups (14.1% (n=46/327) vs 11% (n=35/317), *P* = 0.30) (**Table S7**). Nearly all (n=728/743; 98%) of the clustered isolates belonging to these 14 most common transmission STs carried at least one ESBL or carbapenemase gene.

To investigate whether certain STs were more likely to be transmitted, regardless of AMR genotype, we used logistic regression to model the association of ESBL gene carriage, carbapenemase gene carriage, and ST with transmission, treating each cluster or singleton as a unique strain 'introduction' in a neonatal ward, and defining the outcome for each introduction as either evidence of transmission (i.e. cluster of size ≥2) or no evidence of transmission (i.e. a singleton unclustered case). Transmission was significantly positively associated with carriage of carbapenemase genes (odds ratio (OR) 2.08 [95% confidence interval (CI), 1.18–3.68], p=0.014) or ESBL genes (OR 2.16 [95% CI, 1.06–4.38], p=0.029), and sequence types ST14, ST17, ST35, ST45, ST76, ST218, and ST1741 (compared to rare STs with ≤2 introductions; see **Figure 4** and exact p-values in **Table S8**). **Figure 4B** shows the number of unique introductions vs number resulting in clusters, for all STs, coloured to indicate those that were significantly positively associated with transmission in the model. All STs significantly associated with clusters in the logistic regression model also showed a high crude transmission probability, with median 50% of unique introductions resulting in clusters (range 31–100%), compared with median 25% (range 0–67%) among non-significant STs (**Figure 4B**). Three of the top-5 most common STs (ST307, ST39, ST15) were not significant in the logistic regression model, and these showed large numbers of introductions but with a relatively low proportion of these associated with transmission clusters (n=15/58 (26%), n=10/41 (24%), n=3/20 (15%), respectively).

Figure 4. Logistic regression model for transmission.
(A) Multivariable logistic regression model to assess factors associated with transmission clusters. Each unique 'introduction' (i.e. cluster, or unclustered singleton case) was treated as an observation, with the outcome recorded as transmission (cluster size ≥2) or no transmission (unclustered singleton case). For each cluster, each predictor was assigned the consensus value for that cluster (e.g. if 3 of 4 cases were ESBL, the cluster was recorded as ESBL). All predictors except ST were encoded as binary. Common STs were defined as those observed ≥3 times; rare STs (observed 1–2 times) were categorised as 'Other' and used as the reference category. Points represent the odds ratios for the predictors under the respective model; lines represent the 95% confidence intervals for those odds ratios. Predictors with significant association (p<0.05) are coloured in darker shades. See **Table S8** for exact P values. ESBL+, ESBL or carbapenemase gene carriage (Kleborate resistance score ≥ 1);

CP, carbapenemase producing (Kleborate resistance score ≥ 2). **(B)** Number of unique introductions vs number of clusters, for individual STs. STs are colored to indicate significant association with transmission in the logistic regression model. The dashed line shows y=x, along which the number of unique introductions is equal to the number of clusters. The solid line represents a linear regression line of best fit through the origin (slope 0.18, R^2=0.808).

As K and O antigens have been proposed as potential vaccine targets, we explored their prevalence (based on genomic predictions) and association with transmission in our dataset. Six unique O serogroups were predicted (see **Table S9**), the majority being O1 (n=332/644, 51.6%) or O2 (n=158/644, 24.5%), which were common amongst both clusters and singletons (51.3% vs 51.6%, respectively for O1, 26.9% vs 23.8% for O2). Including O types in the transmission model with ESBL, carbapenemase and ST did not improve model fit (p=0.50 using likelihood ratio test), and no O types were significant (all STs except ST45 remained significant).

Eighty distinct K loci were detected. Forty-three K loci were found in isolates associated with transmission clusters, and 39 of these were also identified in singleton isolates (**Table S10**). Distinct K loci were associated with specific STs, making it difficult to tease apart the effect of K antigens from strain background. For example KL102, which was the most common K locus associated with transmission, was closely associated with ST307: 95% (n=241/253) of KL102 isolates from transmission clusters were ST307, and ST307 accounted for 83% (n=15/18) of KL102 clusters detected. Similarly, 79% (n=42/53) of KL25 cluster isolates belonged to either ST17 (n=33, 62%) or ST607 (n=9, 17%). Including common K loci (each accounting for >1% of unique introductions) in the transmission model together with ESBL, carbapenemase and ST did not improve the model fit (p=0.76 using likelihood ratio test), although KL112 was significantly negatively associated with transmission (OR 0.11 [95% CI, 0.01–0.99], *P*=0.04), with just one cluster of n=8 ST15 isolates out of 15 introductions (ST15, n=12; ST413, n=2; ST17, n=1) observed across 6 sites.

Discussion

Neonatal sepsis caused by *K. pneumoniae* infection is a significant health challenge in Africa and Asia with disproportionately high incidence and mortality rates. Our meta-analysis estimated that over half of all neonatal sepsis cases at the included sites were within transmission clusters, with at least 41% attributable to nosocomial transmission (**Figure 2**).

Transmission analyses typically require detailed data on patient admission, ward movements, and recent healthcare exposures in addition to pathogen sequence data; these are hard to standardise across studies and thus between-study comparisons or meta-analyses are challenging. Here, however, we used studies in which all consecutive neonates with sepsis in a defined physical unit were sampled and the resulting isolates sequenced, allowing us to undertake a standardised clustering analysis based on genetic and temporal distances within each unit.

Furthermore, as our goal was to estimate the fraction of cases linked to others in transmission clusters, rather than trying to resolve specific transmission chains or pathways, our approach was robust to changes in distance thresholds (see **Figures 1, S3**). This is

because lowering clustering thresholds tends to break larger single-linkage clusters into smaller ones (which has no impact on the overall fraction included in clusters), rather than breaking clusters into completely un-linked singleton cases. Variations in genetic and temporal distance thresholds have a greater impact in real-time outbreak investigations, where the goal is to identify specific transmission events and sources. In that context, the choice of thresholds can be adjusted to achieve a desired preference for sensitivity or specificity in cluster detection. Interestingly, previous studies have proposed whole-genome SNV cutoffs of between 21 and 25 for identifying *K. pneumoniae* nosocomial transmission, which is equivalent to the 10 Pathogenwatch core-gene SNV threshold used in our analysis [46–48].

Notably, the attributable transmission fraction observed in our analysis (41.8%, 95% CI 31.1–53.5%), is likely an underestimate due to the conservative nature of our transmission proportion definition. Our assumption that the 'index cases' were not attributable to transmission discounts the very likely possibility that they themselves acquired their infection from the same source as the subsequent cases (e.g., via contaminated equipment or the hands of a carer). The cluster proportion is also likely biased towards underestimation due to missed cases, excluded cases (e.g., children aged >28 days in the same neonatal units), or cases that were acquired in the neonatal unit but not clustered with another sequenced isolate (e.g. a contaminated source may lead to colonisation or even disease in multiple neonates, of which only one individual case of invasive disease is detected). Given these underestimations, even the cluster proportion (57.5%, 95% CI: 46.0–68.2%) probably provides a conservative estimate of the true fraction of sepsis cases amenable to prevention with improved IPC measures.

As with other opportunistic pathogens frequently implicated in hospital-acquired infections, reservoirs and transmission routes for *K. pneumoniae* infection are abundant in the hospital environment, and genomics has been used to resolve specific sources in several studies. These include transmission through direct contact with contaminated surfaces, sinks, cleaning supplies, medical devices, and healthcare personnel [49–53]. Neonates are at high risk of hospital-acquired infections due to their underdeveloped or compromised immune systems, exposure through invasive procedures in critical care settings, repeated handling by multiple caregivers, and long hospital admissions [54,55]. While our study indicates a high impact of IPC deficiencies in neonatal units in LMICs, identifying suitable solutions will require better understanding of risk factors, transmission routes, and sources of contamination. The solutions will also require appropriate testing in clinical trials or complex interventions and subsequently funding for implementation at scale.

We observed a high diversity of *K. pneumoniae* lineages (172 unique STs) implicated in neonatal sepsis cases across hospitals in Asia and Africa (**Table S5**), consistent with previous reports of a highly diverse etiology of *K. pneumoniae*-associated neonatal sepsis [5,20]. A third of these STs were part of at least one transmission cluster, among which 14 STs were identified as commonly transmitted, occurring in ≥3 clusters and ≥2 sites. However, most of these were also common among singleton isolates and accordingly our logistic regression analysis indicated only seven STs that were significantly associated with transmission clusters, compared with rare STs. This finding is consistent with the hypothesis that many different STs can become common causes of transmission clusters, either because they possess traits that render them particularly fit for transmission in the hospital setting, or simply because they are more prevalent (e.g. as gut colonisers in the community)

and therefore have greater stochastic opportunity due to more frequent introductions to the hospital setting. Many of these 14 commonly transmitted STs, including ST11, ST14, ST15, ST17, ST29, ST101 and ST307 are recognised high-risk clones, widely implicated in multidrug-resistant (MDR) hospital-acquired infections worldwide [56–58]. ST39 has been reported less frequently, but is also disseminating rapidly worldwide, including in Africa, where it has been implicated in MDR neonatal outbreaks in The Gambia and Malawi [20,26,59].

The overall high rates of AMR among the *K. pneumoniae* isolates (clustered and singleton) in this study (see **Table S6**) is concerning, as a high degree of resistance is known to be associated with higher rates of nosocomial spread [47,60], a finding that was corroborated in our analysis. We found that cluster cases had significantly higher rates of ESBL and carbapenemase gene carriage compared to single cases, and isolates belonging to the 14 most commonly transmitted STs more frequently carried ESBL genes compared to other STs (**Tables S6, S7**). Carbapenemase and ESBL gene carriage were also independently associated with transmission in the multivariable regression analysis (**Table S8**).

While AMR almost certainly plays a role in the successful persistence of *K. pneumoniae* clones within the hospital setting, other potential factors such as survival on environmental surfaces and colonisation ability are less well characterised [61]. For instance, ST17, the most commonly transmitted ST in this study, was recently demonstrated to colonise the gastrointestinal tracts of children for up to 2 years, a factor that may contribute to its increased transmissibility [62]. ST307 is frequently associated with outbreaks and believed to be adapted to the hospital environment where it can persist for extended periods and rapidly spread among patients [23,61,63]. In this study, ST307 was responsible for the largest identified cluster (involving 188 neonates over a 32-week period at a hospital in Zambia), and 14 other clusters across 8 sites in Kenya, Malawi, Rwanda, Zambia, South Africa and Ghana. However, ST307 was also detected in 43 singleton infections, and only 26% (n=15/58) of detected ST307 introductions in the neonatal units were associated with transmission clusters (similar to the background rate observed across 123 rare STs). This suggests that the frequency of ST307 among hospital outbreaks may reflect a generally high prevalence (i.e., as a gut coloniser) resulting in greater opportunity, in combination with or instead of a specific propensity for transmission in the hospital setting. Further research is needed to determine if specific STs have enhanced risk for transmission once introduced into the hospital setting, and to elucidate potential factors that contribute to their success as hospital-acquired opportunistic pathogens.

In summary, our findings demonstrate the need to improve IPC practices in neonatal care settings in LMICs, and highlight the potential benefits of genomic surveillance of *K. pneumoniae* and other pathogens to assess IPC impacts and/or to support real-time outbreak detection and investigation. Limiting horizontal transmission through improved IPC measures is undoubtedly a crucial prevention strategy that could prevent a significant proportion of neonatal sepsis caused by *K. pneumoniae* and other pathogens, and curb the spread of AMR. Studies have shown that *K. pneumoniae* outbreaks in neonatal units can in principle be effectively controlled by implementing simple IPC measures like contact precautions and improved hand hygiene [19,26,29]. However, to be truly effective in reducing overall disease burden, these measures need to be proactive, rather than reactive, and be integrated into routine practice. The implementation of consistent and effective IPC measures in resource limited settings remains challenging due to resource constraints,

inadequate infrastructure, limited cleaning supplies, understaffing, and limited access to training [64,65]. Whilst this meta-analysis was not suited to probing the determinants of variation in transmission rates, we did find that the three facilities with limited access to piped water displayed high cluster proportions, highlighting the challenges faced in some settings and their impact on hygiene and patient safety. In contrast, the lowest cluster proportions and the lowest isolate counts were observed in consecutive studies at the same large tertiary care hospital in South Africa, which is comparatively well resourced in terms of infrastructure and staffing. Simplified IPC models tailored to resource-constrained settings and focused on training, improved cleaning, and hand hygiene have been proposed and demonstrated to reduce the incidence of neonatal sepsis and mortality [29]. However it is clear that to be effective, such measures must be supported by sustained investment in infrastructure, equipment, staff and training [66]. In addition, to maximise their effectiveness, IPC implementation should be periodically assessed using suitable assessment tools and reviewed as necessary [67–69]. IPC strategies must also be supported by expanding access to blood culture facilities [70,71], accurate diagnostics and robust clinical and microbiological surveillance [72], ideally incorporating whole-genome sequencing, to enable prompt detection of infections, precise transmission tracking, and timely institution of control measures.

Additionally, our findings also have implications for clinical management. WHO guidelines for empirical treatment of neonatal sepsis (third-generation cephalosporins plus gentamicin [73]) are likely to be ineffective against the vast majority of *K. pneumoniae* characterised in this study, which mostly carried ESBL genes, consistent with recent reports from NeoOBS and other studies [11,74]. Access to blood culture facilities, robust clinical diagnostics and susceptibility testing is essential to monitor AMR and update local syndromic guidelines, as is improving access to effective antibiotics in all settings.

Acknowledgments

We thank the participants and their families in all the contributing studies, and the clinical and laboratory staff involved in collection and processing of relevant samples and isolates. This work was supported by the MASSIVE HPC facility (www.massive.org.au). We would also like to acknowledge the expert support of the sequencing and computational genomics teams at the CHOP Microbiome Core (Philadelphia), International Livestock Research Institute (Nairobi), Kilimanjaro Clinical Research Institute (Moshi), Neuberg Center for Genomic Medicine (Ahmedabad), NICD (Johannesburg), Quadram Institute (Norwich), Wellcome Centre for Human Genetics (Oxford), and Wellcome Sanger Institute (Cambridge); and the BARNARDS microbiology and genomics team at Cardiff University.

References

1. World Health Organization. Newborn mortality. 2024 [cited 8 Aug 2024]. Available: https://www.who.int/news-room/fact-sheets/detail/newborn-mortality

2. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106: 745–752. doi:10.1136/archdischild-2020-320217

3. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395: 200–211. doi:10.1016/S0140-6736(19)32989-7

4. Okomo U, Akpalu ENK, Doare KL, Roca A, Cousens S, Jarde A, et al. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. Lancet Infect Dis. 2019;19: 1219–1234. doi:10.1016/S1473-3099(19)30414-1

5. Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat Microbiol. 2021;6: 512–523. doi:10.1038/s41564-021-00870-7

6. Duggan HL, Chow SSW, Austin NC, Shah PS, Lui K, Tan K, et al. Early-onset sepsis in very preterm neonates in Australia and New Zealand, 2007-2018. Arch Dis Child Fetal Neonatal Ed. 2023;108: 31–37. doi:10.1136/archdischild-2021-323243

7. Cailes B, Kortsalioudaki C, Buttery J, Pattnayak S, Greenough A, Matthes J, et al. Epidemiology of UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed. 2018;103: F547–F553. doi:10.1136/archdischild-2017-313203

8. Sands K, Spiller OB, Thomson K, Portal EAR, Iregbu KC, Walsh TR. Early-Onset Neonatal Sepsis in Low- and Middle-Income Countries: Current Challenges and Future Opportunities. Infect Drug Resist. 2022;15: 933–946. doi:10.2147/IDR.S294156

9. Arvay ML, Shang N, Qazi SA, Darmstadt GL, Islam MS, Roth DE, et al. Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study. Lancet Glob Health. 2022;10: e1289–e1297. doi:10.1016/S2214-109X(22)00244-3

10. Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016;4: e752–e760. doi:10.1016/S2214-109X(16)30148-6

11. Russell NJ, Stöhr W, Plakkal N, Cook A, Berkley JA, Adhisivam B, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLOS Med. 2023;20: e1004179. doi:10.1371/journal.pmed.1004179

12. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et al.

Access to effective antimicrobials: a worldwide challenge. The Lancet. 2016;387: 168–175. doi:10.1016/S0140-6736(15)00474-2

13. Li G, Bielicki JA, Ahmed ASMNU, Islam MS, Berezin EN, Gallacci CB, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2020;105: 26–31. doi:10.1136/archdischild-2019-316816

14. Hernandez-Alonso E, Bourgeois-Nicolaos N, Lepainteur M, Derouin V, Barreault S, Waalkes A, et al. Contaminated Incubators: Source of a Multispecies Enterobacter Outbreak of Neonatal Sepsis. Microbiol Spectr. 2022;10: e00964-22. doi:10.1128/spectrum.00964-22

15. Frank Wolf M, Abu Shqara R, Naskovica K, Zilberfarb IA, Sgayer I, Glikman D, et al. Vertical Transmission of Extended-Spectrum, Beta-Lactamase-Producing Enterobacteriaceae during Preterm Delivery: A Prospective Study. Microorganisms. 2021;9: 506. doi:10.3390/microorganisms9030506

16. Kuitunen I, Kekki M, Renko M. Intrapartum azithromycin to prevent maternal and neonatal sepsis and deaths: A systematic review with meta-analysis. BJOG Int J Obstet Gynaecol. 2024;131: 246–255. doi:10.1111/1471-0528.17655

17. Dramowski A, Aucamp M, Beales E, Bekker A, Cotton MF, Fitzgerald FC, et al. Healthcare-Associated Infection Prevention Interventions for Neonates in Resource-Limited Settings. Front Pediatr. 2022;10: 919403. doi:10.3389/fped.2022.919403

18. Zhang X, Li X, Wang M, Yue H, Li P, Liu Y, et al. Outbreak of NDM-1-Producing Klebsiella pneumoniae Causing Neonatal Infection in a Teaching Hospital in Mainland China. Antimicrob Agents Chemother. 2015;59: 4349–4351. doi:10.1128/AAC.03868-14

19. Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, Valderrama Márquez IA, Garzón Aguilar MI, Martinez de la Barrera L, et al. Outbreak of NDM-1-Producing Klebsiella pneumoniae in a Neonatal Unit in Colombia. Antimicrob Agents Chemother. 2013;57: 1957–1960. doi:10.1128/aac.01447-12

20. Heinz E, Pearse O, Zuza A, Bilima S, Msefula C, Musicha P, et al. Longitudinal analysis within one hospital in sub-Saharan Africa over 20 years reveals repeated replacements of dominant clones of Klebsiella pneumoniae and stresses the importance to include temporal patterns for vaccine design considerations. Genome Med. 2024;16: 67. doi:10.1186/s13073-024-01342-3

21. Frenk S, Rakovitsky N, Temkin E, Schechner V, Cohen R, Kloyzner BS, et al. Investigation of Outbreaks of Extended-Spectrum Beta-Lactamase-Producing Klebsiella Pneumoniae in Three Neonatal Intensive Care Units Using Whole Genome Sequencing. Antibiotics. 2020;9: 705. doi:10.3390/antibiotics9100705

22. Cornick J, Musicha P, Peno C, Seager E, Iroh Tam P-Y, Bilima S, et al. Genomic investigation of a suspected Klebsiella pneumoniae outbreak in a neonatal care unit in sub-Saharan Africa. Microb Genomics. 2021;7: 000703. doi:10.1099/mgen.0.000703

23. Magobo RE, Ismail H, Lowe M, Strasheim W, Mogokotleng R, Perovic O, et al. Outbreak of NDM-1– and OXA-181–Producing Klebsiella pneumoniae Bloodstream Infections in a Neonatal Unit, South Africa. Emerg Infect Dis. 2023;29: 1531–1539. doi:10.3201/eid2908.230484

24. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. The Lancet. 2005;365: 1175–1188. doi:10.1016/S0140-6736(05)71881-X

25. Mukherjee S, Mitra S, Dutta S, Basu S. Neonatal Sepsis: The Impact of Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae. Front Med. 2021;8: 634349. doi:10.3389/fmed.2021.634349

26. Okomo U, Senghore M, Darboe S, Bojang E, Zaman SMA, Hossain MJ, et al. Investigation of sequential outbreaks of Burkholderia cepacia and multidrug-resistant extended spectrum β-lactamase producing Klebsiella species in a West African tertiary hospital neonatal unit: a retrospective genomic analysis. Lancet Microbe. 2020;1: e119–e129. doi:10.1016/S2666-5247(20)30061-6

27. Meiring S, Mashau R, Magobo R, Perovic O, Quan V, Cohen C, et al. Study protocol for a population-based observational surveillance study of culture-confirmed neonatal bloodstream infections and meningitis in South Africa: Baby GERMS-SA. BMJ Open. 2022;12: e049070. doi:10.1136/bmjopen-2021-049070

28. Egbe FN, Cowden C, Mwananyanda L, Pierre C, Mwansa J, Lukwesa Musyani C, et al. Etiology of Bacterial Sepsis and Isolate Resistance Patterns in Hospitalized Neonates in Zambia. Pediatr Infect Dis J. 2023;42: 921–926. doi:10.1097/INF.0000000000004008

29. Mwananyanda L, Pierre C, Mwansa J, Cowden C, Localio AR, Kapasa ML, et al. Preventing Bloodstream Infections and Death in Zambian Neonates: Impact of a Low-cost Infection Control Bundle. Clin Infect Dis. 2019;69: 1360–1367. doi:10.1093/cid/ciy1114

30. Phillips LT, Bates M, Coffin SE, Foster-Nyarko E, Kapasa M, Machona S, et al. Transmission dynamics of Klebsiella pneumoniae in a neonatal intensive care unit in Zambia before and after an infection control bundle. medRxiv; 2025. p. 2025.11.12.25340082. doi:10.1101/2025.11.12.25340082

31. Shuping L, Ismail H, Mashau R, Kwenda S, Holt KE, Magobo RE, et al. Enhanced detection of neonatal invasive infection clusters in South Africa using epidemiological and genomic surveillance data. medRxiv; 2025. p. 2025.11.10.25339895. doi:10.1101/2025.11.10.25339895

32. Aiken AM, Rehman AM, de Kraker ME, Madrid L, Kebede M, Labi A-K, et al. Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study. Lancet Infect Dis. 2023;23: 1280–1290. doi:10.1016/S1473-3099(23)00233-5

33. Jain K, Kumar V, Plakkal N, Chawla D, Jindal A, Bora R, et al. Multidrug-resistant sepsis in special newborn care units in five district hospitals in India: a prospective cohort study. Lancet Glob Health. 2025;13: e870–e878. doi:10.1016/S2214-109X(24)00564-3

34. Olwagen CP, Izu A, Khan S, Van der Merwe L, Dean NJ, Mabena FC, et al. Genomic relatedness of colonizing and invasive disease Klebsiella pneumoniae isolates in South African infants. Sci Rep. 2025;15: 8043. doi:10.1038/s41598-025-92517-4

35. Strysko J, Hu W, Mochankana K, John-Thubuka J, Zankere T, Gopolang B, et al. Using Genomic and Traditional Epidemiologic Approaches to Define Complex Transmission

Pathways of Klebsiella pneumoniae Infection in a Neonatal Unit in Botswana, 2022–2023. medRxiv; 2025. p. 2025.11.06.25339637. doi:10.1101/2025.11.06.25339637

36. Amulele AV, Orindi B, Ndumba ML, Tigoi C, Omuoyo D, Kahindi E, et al. Genomic epidemiology of Klebsiella pneumoniae neonatal and infant sepsis in Kenyan hospitals. medRxiv; 2025. p. 2025.10.30.25339129. doi:10.1101/2025.10.30.25339129

37. Stanton TD, Keegan SP, Abdulahi JA, Amulele AV, Bates M, Heinz E, et al. Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: meta-analysis of genome-predicted serotype prevalence and potential vaccine coverage. medRxiv; 2025. p. 2025.06.28.25330253. doi:10.1101/2025.06.28.25330253

38. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance framework and genotyping tool for Klebsiella pneumoniae and its related species complex. Nat Commun. 2021;12: 4188. doi:10.1038/s41467-021-24448-3

39. Stanton TD, Hetland MAK, Löhr IH, Holt KE, Wyres KL. Fast and accurate in silico antigen typing with Kaptive 3. Microb Genomics. 2025;11: 001428. doi:10.1099/mgen.0.001428

40. Argimón S, David S, Underwood A, Abrudan M, Wheeler NE, Kekre M, et al. Rapid Genomic Characterization and Global Surveillance of Klebsiella Using Pathogenwatch. Clin Infect Dis. 2021;73: S325–S335. doi:10.1093/cid/ciab784

41. Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal. 2006;Complex Systems: 1695.

42. Harris SR. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology. bioRxiv; 2018. p. 453142. doi:10.1101/453142

43. Derelle R, Wachsmann J von, Mäklin T, Hellewell J, Russell T, Lalvani A, et al. Seamless, rapid and accurate analyses of outbreak genomic data using Split K-mer Analysis (SKA). bioRxiv; 2024. p. 2024.03.25.586631. doi:10.1101/2024.03.25.586631

44. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2023. Available: https://www.R-project.org/

45. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22: 153–160. doi:10.1136/ebmental-2019-300117

46. Foster-Nyarko E, Cottingham H, Wick RR, Judd LM, Lam MMC, Wyres KL, et al. Nanopore-only assemblies for genomic surveillance of the global priority drug-resistant pathogen, Klebsiella pneumoniae. Microb Genomics. 2023;9: 000936. doi:10.1099/mgen.0.000936

47. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4: 1919–1929. doi:10.1038/s41564-019-0492-8

48. Gorrie CL, Mirčeta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al. Gastrointestinal Carriage Is a Major Reservoir of Klebsiella pneumoniae Infection in

Intensive Care Patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65: 208–215. doi:10.1093/cid/cix270

49. Regev-Yochay G, Margalit I, Smollan G, Rapaport R, Tal I, Hanage WP, et al. Sink-traps are a major source for carbapenemase-producing Enterobacteriaceae transmission. Infect Control Hosp Epidemiol. 2024;45: 284–291. doi:10.1017/ice.2023.270

50. Nakamura I, Yamaguchi T, Miura Y, Watanabe H. Transmission of extended-spectrum β-lactamase-producing Klebsiella pneumoniae associated with sinks in a surgical hospital ward, confirmed by single-nucleotide polymorphism analysis. J Hosp Infect. 2021;118: 1–6. doi:10.1016/j.jhin.2021.08.013

51. Chapman P, Forde BM, Roberts LW, Bergh H, Vesey D, Jennison AV, et al. Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum-β-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal Unit. J Clin Microbiol. 2020;58: 10.1128/jcm.01980-19. doi:10.1128/jcm.01980-19

52. Galdys AL, Marsh JW, Delgado E, Pasculle AW, Pacey M, Ayres AM, et al. Bronchoscope-associated clusters of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2019;40: 40–46. doi:10.1017/ice.2018.263

53. Pearse O, Lester R, Zuza A, Mangochi H, Siyabu P, Tewesa E, et al. Extended-Spectrum Beta-Lactamase Klebsiella pneumoniae on a Malawian neonatal unit is amplified by neonates and transmitted by maternal hands, cots and ward surfaces. medRxiv; 2025. p. 2025.08.13.25333346. doi:10.1101/2025.08.13.25333346

54. Coffin SE, Zaoutis TE. HealthCare–Associated Infections in the Nursery. Infect Dis Fetus Newborn. 2011; 1126–1143. doi:10.1016/B978-1-4160-6400-8.00035-3

55. Collins AS. Preventing Health Care–Associated Infections. In: Hughes RG, editor. Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008. Available: http://www.ncbi.nlm.nih.gov/books/NBK2683/

56. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18: 344–359. doi:10.1038/s41579-019-0315-1

57. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41: 252–275. doi:10.1093/femsre/fux013

58. Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM, et al. Emergence and rapid global dissemination of CTX-M-15-associated Klebsiella pneumoniae strain ST307. J Antimicrob Chemother. 2019;74: 577–581. doi:10.1093/jac/dky492

59. Tryfinopoulou K, Linkevicius M, Pappa O, Alm E, Karadimas K, Svartström O, et al. Emergence and persistent spread of carbapenemase-producing Klebsiella pneumoniae high-risk clones in Greek hospitals, 2013 to 2022. Eurosurveillance. 2023;28: 2300571. doi:10.2807/1560-7917.ES.2023.28.47.2300571

60. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, et al. Genomic

analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci U S A. 2015;112: E3574–E3581. doi:10.1073/pnas.1501049112

61. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, et al. Diversity, virulence, and antimicrobial resistance of the KPC-producing Klebsiella pneumoniae ST307 clone. Microb Genomics. 2017;3: e000110. doi:10.1099/mgen.0.000110

62. Hetland MAK, Hawkey J, Bernhoff E, Bakksjø R-J, Kaspersen H, Rettedal SI, et al. Within–patient and global evolutionary dynamics of Klebsiella pneumoniae ST17. Microb Genomics. 2023;9: 001005. doi:10.1099/mgen.0.001005

63. Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, et al. Klebsiella pneumoniae ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. J Antimicrob Chemother. 2020;75: 896–902. doi:10.1093/jac/dkz550

64. Okomo U, Gon G, Darboe S, Sey ICM, Nkereuwem O, Leigh L, et al. Assessing the impact of a cleaning programme on environmental hygiene in labour and neonatal wards: an exploratory study in The Gambia. Antimicrob Resist Infect Control. 2024;13: 36. doi:10.1186/s13756-024-01393-6

65. Bebell L, Muiru A. Antibiotic use and emerging resistance—how can resource-limited countries turn the tide? Glob Heart. 2014;9: 347–358. doi:10.1016/j.gheart.2014.08.009

66. Penzias RE, Bohne C, Gicheha E, Molyneux EM, Gathara D, Ngwala SK, et al. Quantifying health facility service readiness for small and sick newborn care: comparing standards-based and WHO level-2 + scoring for 64 hospitals implementing with NEST360 in Kenya, Malawi, Nigeria, and Tanzania. BMC Pediatr. 2024;23: 656. doi:10.1186/s12887-024-04578-5

67. Nyantakyi E, Baenziger J, Caci L, Blum K, Wolfensberger A, Dramowski A, et al. Investigating the implementation of infection prevention and control practices in neonatal care across country income levels: a systematic review. Antimicrob Resist Infect Control. 2025;14: 8. doi:10.1186/s13756-025-01516-7

68. CDC. Infection Control Assessment and Response (ICAR) Tool for General Infection Prevention and Control (IPC) Across Settings. In: Healthcare-Associated Infections (HAIs) [Internet]. 2 Dec 2024 [cited 24 Sept 2025]. Available: https://www.cdc.gov/healthcare-associated-infections/php/toolkit/icar.html

69. World Health Organization. Infection prevention and control assessment framework at the facility level. 2018 [cited 24 Sept 2025]. Available: https://iris.who.int/items/e7b27920-31ab-4e84-afd0-dc36055ca266

70. Hyland P, Jacobs J, Hardy L. The cost of blood cultures: a barrier to diagnosis in low-income and middle-income countries. Lancet Microbe. 2025;6: 101125. doi:10.1016/j.lanmic.2025.101125

71. Iregbu K, Zhang R, Zhou Y, Walsh TR. Global health equity and diagnosis of sepsis in low-income and middle-income countries. Lancet Microbe. 2025;6: 101158. doi:10.1016/j.lanmic.2025.101158

72. Vurayai M, Strysko J, Kgomanyane K, Bayani O, Mokomane M, Machiya T, et al. Characterizing the bioburden of ESBL-producing organisms in a neonatal unit using

chromogenic culture media: a feasible and efficient environmental sampling method. Antimicrob Resist Infect Control. 2022;11: 14. doi:10.1186/s13756-021-01042-2

73. World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 2022 [cited 4 Nov 2025]. Available: https://www.who.int/publications/i/item/9789240062382

74. Verani JR, Blau DM, Gurley ES, Akelo V, Assefa N, Baillie V, et al. Child deaths caused by Klebsiella pneumoniae in sub-Saharan Africa and south Asia: a secondary analysis of Child Health and Mortality Prevention Surveillance (CHAMPS) data. Lancet Microbe. 2024;5: e131–e141. doi:10.1016/S2666-5247(23)00290-2

Financial Disclosure Statement

This study was supported by the Gates Foundation [https://www.gatesfoundation.org/] (grants INV049364, INV025280, INV077266 to KEH; INV049641 to KLW; INV003519 to AAiken; INV005180 to NAF; INV041685 to JAB; INV008112 to NPG; INV005567 to CT; INV005691 to DHH; INV005773 to SAM; INV065400 to AMM; INV065400 to SEC), the Fleming Fund [https://www.flemingfund.org/] (grant FF25-286 for SeqAfrica to support sequencing capacity at KCRI), the Thrasher Research Fund [https://www.thrasherresearch.org/] (grant #12036 to DHH), the Center for AIDS Research [https://www.niaid.nih.gov/research/centers-aids-research] (core support grant to SEC), the Wellcome Trust [https://wellcome.org] (grant 217303/Z/19/Z to EH, core support grants 206194 to WSI, 206454 to MLW, 203077/Z/16/Z to KWTRP), and the National Health and Medical Research Council of Australia [https://www.nhmrc.gov.au/] (APP1176192 to KLW). Pfizer [https://www.pfizer.com/] sponsored the sequencing of a subset of isolates from the GBS-COP study for WITS-Vida (SAM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The conclusions and opinions expressed in this work are those of the author(s) alone and shall not be attributed to any funder. Under the grant conditions of the Gates Foundation and Wellcome Trust, a Creative Commons Attribution 4.0 License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Please note works submitted as a preprint have not undergone a peer review process.

Author contribution statement

Conceptualization: Kathryn E Holt
Data Curation: Jabir A Abdulahi, Anne V Amulele, Matthew Bates, Eva Heinz, Weiming Hu, Kajal Jain, Rindidzani Magobo, Courtney P Olwagen, John M Tembo, Tolbert Sonda, Jonathan Strysko, Caroline C Tigoi
Formal Analysis: Erkison Ewomazino Odih, Kathryn E Holt
Funding Acquisition: Ramesh K Agarwal, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Kathryn E Holt, Shabir A Madhi, M Jeeva Sankar, Kelly L Wyres
Investigation: Kyle Bittinger, Jennifer Cornick, Ebenezer Foster-Nyarko, Wilson Gumbi, Steven M Jones, Chileshe Lukwesa, Carolyn M McGann, Ahmed M Moustafa, Patrick Musicha, James CL Mwansa, Moreka L Ndumba, Donwilliams O Omuoyo, Oliver Pearse, Laura T Phillips, Paul J Planet, Charlene MC Rodrigues, Fatou Secka, Kirsty Sands, Jonathan Strysko, Erin Theiller, Allan M Zuza
Methodology: Erkison Ewomazino Odih, Kathryn E Holt, Kelly L Wyres
Resources: Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Kajal Jain, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Anudita Bhargava, Atul Jindal, Ramesh K Agarwal, M Jeeva Sankar, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi,
Software: Erkison Ewomazino Odih, Thomas D Stanton
Supervision: Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Kajal Jain, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Anudita Bhargava, Atul Jindal, Ramesh K Agarwal, M Jeeva Sankar, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi,
Visualization: Erkison Ewomazino Odih, Kathryn E Holt
Writing – Original Draft Preparation: Erkison Ewomazino Odih, Kathryn E Holt
Writing – Review & Editing: All authors.